ストックスクリーナーアプリを入手
488.48
0.44%
-2.15
アフターアワーズ：
488.48
前日終値:
$490.63
開ける：
$490.09
24時間の取引高:
1.33M
Relative Volume:
0.51
時価総額：
$184.46B
収益：
$43.21B
当期純損益:
$6.58B
株価収益率:
28.25
EPS:
17.29
ネットキャッシュフロー:
$6.17B
1週間 パフォーマンス:
-1.97%
1か月 パフォーマンス:
+2.12%
6か月 パフォーマンス:
-8.40%
1年 パフォーマンス:
-19.34%
1日の値動き範囲:
$486.73
$491.52
1週間の範囲:
$482.81
$502.39
52週間の値動き範囲:
$385.46
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
名前
Thermo Fisher Scientific Inc
セクター
電話
(781) 622-1000
住所
168 THIRD AVENUE, WALTHAM, MA
TMO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
488.48 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
206.25 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
641.72 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
118.30 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
187.76 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-24 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-07-11 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | ダウングレード | UBS | Buy → Neutral |
| 2025-01-10 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-14 | 開始されました | Redburn Atlantic | Buy |
| 2024-10-01 | 開始されました | Stephens | Overweight |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-03-18 | 再開されました | Citigroup | Neutral |
| 2024-01-24 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-01-08 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-10-26 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-09-06 | 再開されました | Citigroup | Buy |
| 2023-07-19 | 開始されました | Raymond James | Outperform |
| 2023-07-19 | 繰り返されました | Robert W. Baird | Outperform |
| 2023-07-13 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | 繰り返されました | Barclays | Overweight |
| 2022-12-14 | 開始されました | Deutsche Bank | Buy |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-10-27 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2022-08-25 | 開始されました | Credit Suisse | Neutral |
| 2022-04-25 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | 再開されました | Barclays | Overweight |
| 2021-10-20 | アップグレード | Citigroup | Neutral → Buy |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-08-05 | 再開されました | Credit Suisse | Outperform |
| 2021-07-16 | 開始されました | The Benchmark Company | Buy |
| 2021-03-18 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | 開始されました | Barclays | Overweight |
| 2021-01-08 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-02 | 開始されました | Goldman | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | 開始されました | Atlantic Equities | Overweight |
| 2020-09-14 | 開始されました | Morgan Stanley | Overweight |
| 2020-08-20 | 再開されました | JP Morgan | Overweight |
| 2020-07-15 | アップグレード | Cleveland Research | Neutral → Buy |
| 2020-07-07 | 繰り返されました | Needham | Buy |
| 2020-04-23 | 繰り返されました | Needham | Buy |
| 2020-01-31 | 繰り返されました | Needham | Buy |
| 2020-01-22 | 開始されました | Credit Suisse | Neutral |
| 2020-01-08 | 開始されました | Wells Fargo | Equal Weight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2019-11-15 | 開始されました | Stifel | Buy |
| 2019-07-25 | 繰り返されました | Needham | Buy |
| 2019-07-16 | ダウングレード | Needham | Strong Buy → Buy |
| 2019-05-30 | 開始されました | Wolfe Research | Outperform |
| 2019-05-23 | 繰り返されました | Needham | Strong Buy |
| 2019-04-22 | 繰り返されました | Needham | Strong Buy |
| 2019-04-16 | 繰り返されました | BofA/Merrill | Buy |
すべてを表示
Thermo Fisher Scientific Inc (TMO) 最新ニュース
Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034 - GlobeNewswire Inc.
Advancing Process Development With The 5L DynaDrive Single-Use Bioreactor A Paradigm Shift From Glass Benchtop Bioreactors - Bioprocess Online
Lab Equipment Market and Supply Chain Forecasts 2025-2030 - GlobeNewswire
Lab Equipment Market and Supply Chain Forecasts 2025-2030 Featuring Eppendorf, Beckman Coulter, Agilent Technologies, Thermo Fisher Scientific, Waters Corp. & More - Yahoo Finance
Why Thermo Fisher Scientific Stock Was Topping the Market Today - MSN
Thermo Fisher Positioned As Biopharma's Partner Of Choice - Benzinga
The Zacks Analyst Blog Highlights IBM, Goldman Sachs Group And Thermo Fisher Scientific - Barchart.com
Biodesix Designated Thermo Fisher Center of Excellence for NGS-Based Diagnostics. - AInvest
Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics - GlobeNewswire
Major Diagnostic Partnership: Biodesix Joins Elite Group as Thermo Fisher Center of Excellence for Cancer Testing - Stock Titan
This Thermo Fisher Scientific Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
The Zacks Analyst Blog Highlights IBM, Goldman Sachs Group and Thermo Fisher Scientific - Yahoo Finance
William Blair Initiates Thermo Fisher Scientific at Outperform - MarketScreener
Pharmaceutical Inspection Machines Market to Reach $1.66 Billion by 2030, Led by Key Players Mettler-Toledo, Thermo Fisher Scientific, Sartorius, Syntegon Technology, and Krones - AInvest
Stifel Reaffirms Buy on Thermo Fisher (TMO) Despite Price Target Cut - MSN
Wells Fargo Reaffirms ‘Buy’ Rating on Thermo Fisher Scientific Inc. (TMO) - MSN
Top Stock Reports for IBM, Goldman Sachs & Thermo Fisher - The Globe and Mail
Automated Biological Microscope Market Exclusive Report with - openPR.com
Is Wall Street Bullish Or Bearish On Thermo Fisher Scientific Stock? - Barchart.com
Thermo Fisher Scientific Inc. (NYSE:TMO) Q1 2025 Earnings Call Transcript - MSN
Saliva-based Screening Market CAGR 7.70% Trends with Thermo - openPR.com
Thermo Fisher Scientific's Strategic Momentum and Institutional Confidence: A Top Buy in the Evolving Biotech Landscape - AInvest
Thermo Fisher Scientific (TMO): A Buy Rating Reinforced by Strategic M&A Adjustments and Strong Earnings Momentum - AInvest
Day 7 of Gains Streak for Thermo Fisher Scientific Stock with 8.9% Return (vs. -5.8% YTD) [8/15/2025] - Trefis
Thermo Fisher's 0.82% Gain on 66th-Ranked $1.2B Volume Driven by FDA-Approved Cancer Diagnostic Expansion - AInvest
Is Thermo Fisher Scientific Inc.’s growth already priced inPortfolio Risk Summary & Expert Curated Trade Ideas - thegnnews.com
Is Now a Good Time to Reenter Thermo Fisher Scientific Inc.2025 Winners & Losers & Reliable Price Action Trade Plans - beatles.ru
Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR | MarketsandMarkets™ - PR Newswire UK
Digital health companies list reveals industry leaders and newcomers in Silicon Valley - The Business Journals
Thermo Fisher Navigates 92nd in $940M Volume Amid FDA Approval and Sanofi Strategic Expansion - AInvest
Syncell and Thermo Fisher Collaborate on High-Resolution Spatial Proteomics Workflow - AInvest
Taiwan's Syncell partners with Thermo Fisher to advance high-resolution spatial proteomics - BioSpectrum Asia
Thermo Fisher teams up with Syncell for spatial proteomics integration - Yahoo Finance
HIV Diagnostics Company Evaluation Report 2025 | Abbott, Siemens Healthineers, and Thermo Fisher Scientific Lead the Market with Innovative Portfolios and Strategic Expansion - Yahoo Finance
Recombinant DNA Technology Market Trends, Dynamic Innovation, - openPR.com
Here's How Much a $1000 Investment in Thermo Fisher Scientific Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Toast, Amazon, Thermo Fisher Scientific And An Industrial Stock On CNBC's 'Final Trades' - Benzinga
Syncell Announces Strategic Co-Marketing Agreement to Advance High-Resolution Spatial Proteomics - Business Wire
Major biopharma firm sells Sunnyvale building in real estate consolidation - The Business Journals
Saudi Arabia Clinical Chemistry Analyzer Market Forecast and Company Analysis Report 2025-2033 Featuring Thermo Fisher Scientific, Abbott, Siemens, Danaher, J&J, Sysmex ADR, HORIBA, Hitachi - GlobeNewswire
Mexico Microcarrier Market Trends and Company Analysis Report 2025-2033 Featuring BD, Thermo Fisher Scientific, Merck, Eppendorf, Danaher, Sartorius, Bio Rad, Corning, Lonza Group, Getinge - Yahoo Finance
Apoptosis Market Future Business Opportunities 2025-2032 | - openPR.com
Heron Therapeutics enters supply agreement with Patheon and Thermo Fisher - Investing.com Nigeria
Thermo Fisher Scientific (TMO) Oncomine Dx Test Gains FDA Approval for NSCLC Treatment - simplywall.st
FDA approves Thermo Fisher’s diagnostic test for new NSCLC treatment - Medical Device Network
US Durable Medical Equipment Market Forecast and Competitive Landscape Report 2025-2033 | Invacare, NOVA, Inogen, Thermo Fisher Scientific, Abbott, Medtronic, Baxter, B. Braun, Boston Scientific, BD - Yahoo Finance
Becton, Dickinson shares rise 1.26% premarket after Thermo Fisher Scientific gets US FDA approval for lung cancer test. - AInvest
Thermo Fisher Scientific: A Premium Growth Story at a Discount Valuation - AInvest
Thermo Fisher: Growth Acceleration And Margin Expansion Should Drive The Upside - Seeking Alpha
Thermo Fisher's Stock Climbs 0.36% on FDA Diagnostic Approval Surges to 119th in Activity with $790M Volume - AInvest
Thermo Fisher Receives FDA Approval for NGS-Based Companion Diagnostic for New Non-Small Cell Lung Cancer Treatment - Business Wire
Thermo Fisher Scientific Inc (TMO) 財務データ
収益
当期純利益
現金流量
EPS
0.71%
0.06%
大文字化:
|
ボリューム (24 時間):